Brooklyn ITX is a clinical-stage bioresearch company developing IRX-2, an important new immunotherapy candidate for cancer.  Brooklyn ITX is developing novel immunotherapies based upon reversing immune suppression that is typically seen in patients with cancer and other diseases. The lead product, IRX-2, is a primary cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells, and natural killer cells.